Filing Details
- Accession Number:
- 0001209191-23-011704
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-22 16:48:42
- Reporting Period:
- 2023-02-17
- Accepted Time:
- 2023-02-22 16:48:42
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1789815 | Ourania Tatsis | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Chief Reg. & Quality Off. | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-02-17 | 4,498 | $292.85 | 60,947 | No | 4 | F | Direct | |
Common Stock | Disposition | 2023-02-21 | 4 | $291.01 | 60,943 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-02-21 | 145 | $292.85 | 60,798 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-02-21 | 207 | $293.83 | 60,591 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-02-21 | 124 | $294.77 | 60,467 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | F | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
- Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $292.85 (range $292.37 to $293.36).
- Open market sales reported on this line occurred at a weighted average price of $293.83 (range $293.39 to $294.38).
- Open market sales reported on this line occurred at a weighted average price of $294.77 (range $294.42 to $295.37).